Completed
PHASE1
INTERVENTIONAL
NCT05611957
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 5 weeks, excluding screening.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered SC.
Primary Outcomes
Measure:
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943
TimeFrame:
Predose up to 31 days postdose
Description:
PK: AUC0-∞ of LY3437943
Measure:
PK: Maximum observed concentration (Cmax) of LY3437943
TimeFrame:
Predose up to 31 days postdose
Description:
PK: Cmax of LY3437943
Trial Information
NCT ID
NCT05611957
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025